Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2012
03/01/2012US20120052115 Nanocarrier therapy for treating invasive tumors
03/01/2012US20120052097 Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
03/01/2012US20120052094 Agonists of Neurotrophin Receptors and Their Use as Medicaments
03/01/2012US20120052088 Pneumococcal vaccine and uses thereof
03/01/2012US20120052083 MUTANT CyaA POLYPEPTIDES AND POLYPEPTIDE DERIVATIVES SUITABLE FOR THE DELIVERY OF IMMUNOGENIC MOLECULES INTO A CELL
03/01/2012US20120052080 Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
03/01/2012US20120052079 Compositions, Kits, and Methods for Predicting Anti-Cancer Response to Anthracyclines
03/01/2012US20120052078 Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
03/01/2012US20120052077 Therapeutic modulation of vaginal epithelium boundary lubrication
03/01/2012US20120052076 Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
03/01/2012US20120052074 Human monoclonal antibodies to activin receptor-like kinase-1
03/01/2012US20120052073 Antibodies Directed to Angiopoietin-2 And Uses Thereof
03/01/2012US20120052072 High affinity human antibodies to human il-4 receptor
03/01/2012US20120052071 Tumor markers and methods of use thereof
03/01/2012US20120052070 Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both
03/01/2012US20120052068 Autophilic antibodies and method of making the same
03/01/2012US20120052065 Methods of treatment using ctla4 mutant molecules
03/01/2012US20120052064 Anti-hgf antibody combinational cancer therapies
03/01/2012US20120052063 Automated detection of breast cancer lesions in tissue
03/01/2012US20120052062 Methods for Treatment of Non-Small Cell Lung Cancer
03/01/2012US20120052061 Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
03/01/2012US20120052060 Human Antibody Molecules For IL-13
03/01/2012US20120052059 Regulatory b cells and their use
03/01/2012US20120052041 Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
03/01/2012US20120052040 Polymer compositions and methods for their use
03/01/2012US20120052019 Certain chemical entities, compositions, and methods
03/01/2012US20120052015 End-capped polymers
03/01/2012US20120052007 Peripheral blood sparc binding antibodies and uses thereof
03/01/2012US20120052005 Combination therapy to improve drug efficiency
03/01/2012US20120052003 Microorganisms for preventing and treating neoplasms accompanying cellular therapy
03/01/2012DE102010035744A1 Imidazolonylchinoline Imidazolonylchinoline
03/01/2012CA2809388A1 Crystal of a free tricyclic pyrazolopyrimidine derivative
03/01/2012CA2809362A1 Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
03/01/2012CA2809256A1 Compounds for treatment of cancer
03/01/2012CA2809153A1 Immunotherapeutic method for treating prostate cancer
03/01/2012CA2809120A1 Crystal of tricyclic pyrazolopyrimidine derivative
03/01/2012CA2809089A1 Anti-ox40 antibodies and methods of using the same
03/01/2012CA2809086A1 Pure intermediate
03/01/2012CA2808841A1 Antimetastatic compounds
03/01/2012CA2808418A1 Antibodies to matrix metalloproteinase 9
03/01/2012CA2808359A1 Certain chemical entities, compositions, and methods
02/2012
02/29/2012EP2423328A2 Compounds and methods associated with differential methylation of human papilloma virus genomes in epithelial cells
02/29/2012EP2423311A1 Method for preparing cell pharmaceutical
02/29/2012EP2423310A1 Cancer antigen helper peptide
02/29/2012EP2423231A2 PRLR-specific antibody and uses thereof
02/29/2012EP2423228A1 Antibody containing igg2 having amino acid mutation introduced therein
02/29/2012EP2423227A1 Human antibodies to human delta like ligand 4
02/29/2012EP2423215A1 Prodrugs based on gemcitabine structure as well as synthetic method and application thereof
02/29/2012EP2423213A1 Preparation and use of novel antibiotic, anticancer compounds and derivatives thereof
02/29/2012EP2423208A1 Pharmaceutically active compounds as Axl inhibitors
02/29/2012EP2423196A1 5, 6 or 7-substituted-3-phenylisoquinolinamine derivatives and therapeutic use thereof
02/29/2012EP2422849A1 Composition of Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
02/29/2012EP2422848A1 Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
02/29/2012EP2422818A2 Process to produce a diclofenac cyclodextrin conjugate
02/29/2012EP2422816A1 A drug composition for treating tumor with polymeric micelle encapsulating antineoplastic
02/29/2012EP2422815A1 Pharmaceutical composition of tegafur and natural flavonoid derivative catechin for potentiating antitumour effect and for treating tumours
02/29/2012EP2422813A1 Agent for regulating composition ratio of intestinal bacterial flora
02/29/2012EP2422793A1 Pharmaceutical Compositions For Dehydrating, Atrophying And Eliminating Pathological Tissues
02/29/2012EP2422788A2 Benzodiazepines and compositions and uses thereof
02/29/2012EP2422785A1 Method for predicting therapeutic effect of chemotherapy on renal cell cancer
02/29/2012EP2422784A1 Composition of TEGAFUR, caffeic acid phenethyl ester (CAPE) and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
02/29/2012EP2422779A1 Selective ep4 receptor agonistic substance for treatment of cancer
02/29/2012EP2422776A1 Polyarginine nanocapsules
02/29/2012EP2421968A1 Method for the treatment of acute myeloid leukemia
02/29/2012EP2421888A1 A novel cell and therapeutical and diagnostical methods based thereon
02/29/2012EP2421882A2 Angiogenesis inhibitors
02/29/2012EP2421879A2 Novel 7-deazapurine nucleosides for therapeutic uses
02/29/2012EP2421877A1 Anionic conjugates of glycosylated bacterial metabolite
02/29/2012EP2421872A1 Thia-triaza-as-indacenes as pi3-kinases inhibitors for the treatment of cancer
02/29/2012EP2421871A1 Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer
02/29/2012EP2421866A1 3,3'-spiroindolinone derivatives and their use for cancer
02/29/2012EP2421864A1 1-pyrazolo[4,3-c]isoquinoline derivatives, preparation thereof and therapeutic use thereof
02/29/2012EP2421846A1 5-alkynyl-pyridines
02/29/2012EP2421844A1 Thiophene inhibitors of ikk-b serine-threonine protein kinase
02/29/2012EP2421833A1 Resorcinol derivatives as hsp90 inhibitors
02/29/2012EP2421612A1 Heterocyclic compounds as mek inhibitors
02/29/2012EP2421562A1 Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
02/29/2012EP2421537A1 Pyrazolylaminopyridines as inhibitors of fak
02/29/2012EP2421536A1 Methods of treatment for solid tumors
02/29/2012EP2421506A2 Nanocarrier therapy for treating invasive tumors
02/29/2012EP2328866B1 3',6-substituted indirubins and their biological applications
02/29/2012EP2212301B1 An improved process for preparation of letrozole and its intermediates
02/29/2012EP2203447B1 Inhibitors of the interaction between mdm2 and p53
02/29/2012EP2176255B1 Andrographolide derivatives and use thereof in manufacture of medicaments
02/29/2012EP2123649B1 3-pyrrolo-cyclohexylene-2-dihydro-indolinone derivatives and uses thereof
02/29/2012EP2040719B1 Use of cells derived from adipose tissue for the preparation of an anti-tumour medicament
02/29/2012EP2010221B1 Antibody-rnase-conjugate
02/29/2012EP1975158B9 Novel pyrrole derivatives with histone deacetylase inhibitor activity
02/29/2012EP1909804B1 Glucosamine and derivatives thereof useful as transglutaminase inhibitors in the treatment of a nervous system disorder
02/29/2012EP1871375B1 Carboline derivatives useful in the treatment of cancer
02/29/2012EP1542997B1 Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
02/29/2012EP1465642B1 Protection against the neurotoxicity of oxaliplatin through the administration of calcium and magnesium
02/29/2012EP1390383B1 Antisense permeation enhancers
02/29/2012EP1002091B1 Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
02/29/2012CN1884301B Targeted function superantigen and its preparation method and use
02/29/2012CN1351656B Human liver progenitors
02/29/2012CN102365297A Novel anti-alpha5beta1 antibodies and uses thereof
02/29/2012CN102365296A Methods for producing mixtures of antibodies
02/29/2012CN102365271A Heterocyclic compounds as autotaxin inhibitors
02/29/2012CN102365269A Novel therapeutic agent for cognitive impairment
1 ... 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 ... 2211